Navigation Links
ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
Date:12/16/2009

MOUNTAIN VIEW, Calif., Dec. 16 /PRNewswire/ -- ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

CCX354 is a highly potent and selective antagonist of CCR1, a chemokine receptor that drives the recruitment of immune cells, such as monocytes and macrophages, associated with the inflammation underlying certain autoimmune diseases, including RA. By selectively blocking the CCR1 receptor, CCX354 is designed to reduce the infiltration of inflammatory cells into the joints of RA patients and inhibiting the subsequent joint destruction while minimizing the potential for off-target effects, thus providing a wider therapeutic window than currently approved therapies. The high potency and selectivity of the molecule are expected to provide continuous receptor coverage throughout the dosing period which is thought to be critical for efficacy. Successful completion of single and multiple ascending dose Phase 1 studies in healthy volunteers showed that CCX354 was safe and well-tolerated.

"Initiation of a Phase 2 clinical development program for CCX354 marks yet another important milestone for ChemoCentryx and represents a unique opportunity to thoroughly evaluate a new mechanism of action for the potential treatment of rheumatoid arthritis," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We believe our CCR1 antagonist is best-in-class, surpassing the properties of previous molecules in this space, particularly in its ability to continuously cover the disease target, the CCR1 receptor. This study builds on our recent clinical success of demonstrating efficacy for Traficet-EN(TM), a novel drug which targets another chemokine receptor, in patients suffering from Crohn's disease. We
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
2. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
6. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
7. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
8. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
9. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
10. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
11. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... MEDITE Group acquired by CytoCore, Inc. (OTCBB: CYOE) on April ... quarter sales ended September 30, 2014 of $8.7 million and ... ended September 2014 and a $38,000 loss for the quarter ... is usually a seasonable weak period due to the summer ... countries worldwide, we are proud to announce record sales for ...
(Date:11/21/2014)... PARK, Md. , Nov. 21, 2014  The ... today will host the ceremonial groundbreaking of the new ... College Park. The new building will cultivate transformative new ... health.  Taking place at 10:00 a.m. on ... in the Paint Branch Parking Lot, adjacent to the ...
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
Breaking Medicine Technology:CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
(Date:11/24/2014)... California (PRWEB) November 24, 2014 ... USD 6.19 billion by 2020, according to a ... incidence rates of cardiac arrhythmias clubbed with growing ... of this market. Though still in the budding ... significant rise in usage rates in the recent ...
(Date:11/24/2014)... November 24, 2014 Volpara Solutions ... 1.2 at the 100th Annual Meeting of the ... 5, 2014 (RSNA Booth 1752 – South Hall). ... VolparaAnalytics and the rest of its innovative suite ... VolparaDoseRT, which enable personalized measurements of volumetric density, ...
(Date:11/24/2014)... 24, 2014 Residents of retirement communities ... this year’s SENIORS GOT TALENT, an annual online talent ... piano players to classic crooners, to seniors partying on ... adults are indeed living young. , “SENIORS GOT TALENT, ... a cash prize, has always been about highlighting the ...
(Date:11/24/2014)... TX (PRWEB) November 24, 2014 Olaparib ... ribose polymerase (PARP) and is one of the first ... vulnerable to creating some types of melanoma, and are ... this also sometimes gives their malignancies a exclusive weaknesses, ... PARP to fix their DNA and allow them to ...
(Date:11/24/2014)... The Holiday Inn Westbury - Long ... Children's Association to donate various items consisting of ... other such items.The Association's program is aimed toward helping ... in nursing homes, assisted living facilities and nursing homes. ... being of seniors throughout the Long Island area. The ...
Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3
... - Treating relapsed follicular lymphoma patients with a milder ... transplant from a donor resulted in long-term complete remission ... researchers at The University of Texas M. D. Anderson ... the American Society of Hematology. , The two ...
... , , MONDAY, Dec. 10 (HealthDay News) -- Scientists believe ... BRCA1 can cause some breast cancers. , Basal-like breast ... all breast cancers. BBCs generally have a poor prognosis, ... with hereditary mutations in the BRCA1 gene, the researchers ...
... parents who divorce necessarily exhibit a diminished capacity to ... study conducted by University of Alberta sociology professor Lisa ... behavior, and that there are actually more similarities than ... , The study used data from the 1994 and ...
... Pregnancy: Typically, it is an,event in a woman,s life that ... of a new baby into the world, and it is ... do,happen to arise, help is readily available., But this ... the,experiences in the Sub-Saharan region of Africa, where pregnancy is ...
... to Give Emotional Support and Show Gratitude to ... Our Injured Service Members, ARLINGTON, Va., ... get into the holiday spirit, here,s a great item,for your "to-do" list: ... service that you appreciate (and haven,t forgotten) his,or her sacrifices for our ...
... a vaccine targeting Epstein-Barr virus (EBV) may prevent infectious mononucleosis, ... is published in the December 15 issue of The Journal ... member of the herpes virus family and one of the ... developed countries such as the United States having been infected. ...
Cached Medicine News:Health News:Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma 2Health News:Mutated Suppressor Gene Leads to a Type of Breast Cancer 2Health News:Mutated Suppressor Gene Leads to a Type of Breast Cancer 3Health News:Massive study finds parenting practices don't suffer during divorce 2Health News:The Reality of Pregnancy in Sub-Saharan Africa: Author Shares Truth About Pregnancy in a Region Where 1 in 16 Women Die from Complications 2Health News:Just in Time for the Holidays, The USO and CarePages.com Launch 'Operation: Show You Care' 2Health News:Just in Time for the Holidays, The USO and CarePages.com Launch 'Operation: Show You Care' 3Health News:Vaccine shows promise in preventing mono 2
... Rocking Shaker provides the exact agitation ... The very slow to fast speed ... provide a gentle wave motion that ... blotted membranes to achieve faster, more ...
Multi-Tier Shaker...
... Wellmix is a high-quality four-place microplate shaker ... shaking speed is adjustable from 100 to ... and a small orbit ensure effective shaking ... is quick and easy to set for ...
Inquire...
Medicine Products: